Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O15263

UPID:
DFB4A_HUMAN

ALTERNATIVE NAMES:
Beta-defensin 2; Defensin, beta 2; Skin-antimicrobial peptide 1

ALTERNATIVE UPACC:
O15263; Q52LC0

BACKGROUND:
Defensin beta 4A, known alternatively as Skin-antimicrobial peptide 1, exhibits significant antimicrobial effects against a variety of pathogens, including Gram-negative and Gram-positive bacteria, with a pronounced efficacy against Gram-negative strains. It also demonstrates activity against the yeast C.albicans by disrupting cell membranes. Beyond its antimicrobial function, Defensin beta 4A interacts with CCR6, a chemokine receptor, to induce the movement of dendritic cells and memory T cells, playing a vital role in immune surveillance and response.

THERAPEUTIC SIGNIFICANCE:
The exploration of Defensin beta 4A's functions offers promising avenues for therapeutic intervention. Its antimicrobial properties and role in immune cell regulation present it as a valuable target for the development of novel treatments for infectious diseases and immune-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.